FDA Announces Implementation Of
To print this article, all you need is to be registered or login on Mondaq.com. In March 2020, because of COVID-19 health risks and travel restrictions, the Food and Drug Administration (FDA) suspended most of its inspection program, both in the United States and abroad. The agency limited inspections to those that were priority or mission critical, including some pre-approval inspections for important new therapies and some for-cause inspections. During the pandemic, FDA also increased its use of some alternatives to in-person inspections, such as relying on inspectio...
Source: mondaq.com
